Rezolute, Inc.’s Post

Source: (Neoplasma) Study assesses serum vitamin D levels in renal cell carcinoma, bladder cancer, and prostate cancer patients using UPLC-MS/MS. Analyzed 170 subjects; found lower 25(OH)D, 25(OH)D3, and C3-epi levels in cancer patients compared to healthy controls, indicating vitamin D deficiency. 25(OH)D3 effectively distinguishes cancer patients from healthy individuals.

𝓥𝓲𝓷𝓬𝓻𝓲𝓼𝓽𝓲𝓷𝓮 𝓜𝓮𝓬𝓱𝓪𝓷𝓲𝓼𝓶 𝓸𝓯 𝓐𝓬𝓽𝓲𝓸𝓷, 𝓘𝓷𝓭𝓲𝓬𝓪𝓽𝓲𝓸𝓷𝓼, 𝓟𝓱𝓪𝓻𝓶𝓪𝓬𝓸𝓴𝓲𝓷𝓮𝓽𝓲𝓬𝓼 𝓪𝓷𝓭 𝓐𝓭𝓿𝓮𝓻𝓼𝓮 𝓔𝓯𝓯𝓮𝓬𝓽𝓼: , 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 🌈 A vinca alkaloid called vincristine is used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦 𝐨𝐟 𝐀𝐜𝐭𝐢𝐨𝐧 🌈 Vincristine is a microtubule-disrupting medication that is a member of the vinca alkaloid class of chemotherapy medications. The main way that vincristine works is through interfering with the dynamics of microtubules, especially in the M and S phases, which are crucial for cell division and other biological functions. Vincristine also inhibits the synthesis of proteins and nucleic acids by preventing the use of glutamic acid as one of its mechanisms of action. 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐤𝐢𝐧𝐞𝐭𝐢𝐜𝐬 🌈 Vincristine is administered via an IV route and is rapidly and completely absorbed into the systemic circulation. Vincristine is extensively metabolized in the liver, mostly via the CYP (cytochrome P450) enzyme system, which includes the enzymes CYP3A4 and CYP3A5.[11] 4-O-desacetyl-vincristine is the main metabolite; it has some anticancer activity but is noticeably less effective than the original medication. N-deformyl-vincristine, N-deformyl-4-O-desacetyl-vincristine, and 4-O-desacetyl-N-deformyl-vincristine are some other minor metabolites. Genetic variations in the CYP3A4 and CYP3A5 enzymes, as well as medication interactions involving inducers or inhibitors of these enzymes, all impact vincristine metabolism. 𝐀𝐝𝐯𝐞𝐫𝐬𝐞 𝐄𝐟𝐟𝐞𝐜𝐭𝐬 🌈 Vincristine has a number of adverse effects that might vary in intensity and impact different organ systems. The cardiovascular, central nervous system, dermatological, endocrine and metabolic, gastrointestinal, genitourinary, hepatic, renal, pulmonary, neuromuscular, otic, and ocular systems are among the prominent organ systems that vincristine may adversely impact.

Share here my recent published article in high impact factor journal, Saudi Dental Journal:A Systematic Review on Vitamin D Deficiency with Caries, Periodontitis, and Oral Cancer. You are welcome to share with your friend if you find it interested.

High insulin levels linked to increased pancreatic #cancer risk: A new study from the University of British Columbia has uncovered a direct link between high insulin levels and pancreatic cancer, shedding light on why #obesity and #Type2diabetes increase cancer risk. The research, published in Cell Metabolism, shows that excessive insulin overstimulates pancreatic acinar cells, leading to inflammation and the formation of precancerous cells. https://lnkd.in/e-e34qA4

In a small sample of pancreatic cancer patients (n = 34), high dose Vitamin C supplementation alongside traditional chemotherapy significantly increased survival in a Phase II study. Importantly, no additional adverse events were observed in this population relative to standard of care alone. Interesting study, and another instance of non-traditional approaches to enhance the efficacy of existing treatments! Simple, cheap, and safe. Would need to see a larger, more robust Phase III trial, but exciting nonetheless. Read the paper here: https://lnkd.in/eACdZDpq

✨ MAINTRAC®: HOW IT WORKS ✨ Maintrac® helps doctors monitor epithelial tumour cells 🧬, informing collaborative clinical decisions. 👥 CETCs indicate the risk of blood-borne metastases. Monitoring these cells aids personalised interventions. 🎯 Maintrac® uses a simple blood sample to measure CETCs in real-time, without sample manipulation. It's highly reproducible, with the SIMFO GmbH lab in Bayreuth, Germany, ISO 15189 accredited. 📊 Over 100 peer-reviewed articles on Maintrac® have been published. 📚 Maintrac® tracks therapeutic responses as CETC numbers correlate with tumour growth and metastasis. 📈 🧬 MAINTRAC® CAN: ✔️ Monitor therapy effects ✔️ Test agents against patient-specific cells for tailored therapies ✔️ Track hormone therapy effectiveness ACCURACY: 📏 Repeated measurements provide consistent results. For more information regarding Maintrac® please see here: https://aonm.org/maintrac/ 📧 Email support@aonm.org See Maintrac® publications for more details https://lnkd.in/ekbw95wW 📝 IMPORTANT NOTES: 1. Maintrac® is not intended to be used as a diagnostic or screening approach. It may be used for tracking the progression or remission of tumours of epithelial origin through its detection of circulating epithelial tumour cells (CETCs) in the blood. 🩸 The approach has multiple applications, including helping to inform clinical judgment in the provision of functional or integrative support for patients or clients. 👩⚕️👨⚕️. 2. If Maintrac® to be used to inform cancer treatment directly, or to monitor the interaction of chemotherapeutic agents with CETCs or CSCs (circulating stem cells), the tests must be overseen by a registered medical practitioner or oncologist. 🩺

Intriguing new role for GLP-1R in T cells opens doors to novel therapies in transplantation and cancer. GLP-1R, known for regulating glucose in pancreatic β cells, is also expressed by T lymphocytes during immune responses. In this Cell article, GLP-1Rpos T cells expanded and infiltrated grafts in transplant models, showing significant differences from GLP-1Rneg T cells. GLP-1R signaling prolongs allograft survival and reduces immune response, while its antagonism boosts anti-tumor immunity in colorectal cancer. #GLP1R #Tcell #regulation #cancer #immunotherapy #transplantation https://lnkd.in/dW_SGAe8

Today is Glioblastoma Awareness Day, a crucial moment to unite in the fight against one of the most aggressive forms of brain cancer. With survival times averaging only 15-18 months from diagnosis and a five-year survival rate under 10 percent, the urgency for innovative treatments has never been greater. At BPGbio, Inc., we are actively working on developing innovative treatments for Glioblastoma Multiforme (GBM). Derived from our NAi platform, our drug candidate BPM31510, currently in phase 2b trial in combination with vitamin K, has shown early but promising results in patients with newly diagnosed GBM. Preclinical studies suggested that there is a hallmark shift in the tumor microenvironment (TME) induced by BPM31510 which modulates mitochondrial oxidative phosphorylation in highly aggressive tumors, making BPM31510 a sensitizer for radiation and chemotherapy. Glioblastoma Awareness Day is a reminder of the urgent need for continued research, funding, and support for patients and their families. Let's raise awareness and advocate for advancements in treatment options that can offer hope and improve outcomes for those affected by this devastating disease. Learn more: https://lnkd.in/gpuKExVX #GlioblastomaAwareness #GBMDay #BPGbio #BrainCancerResearch #AIinHealthcare #InnovativeTherapies #Phase2Trails #BPM31510IV #oncology #chemotherapy #sensitizer #cancer #AIdrugdiscovery #AI #curecancer

#Akkermansia may improve the response to chimeric antigen receptor (#CAR) T-cell therapy in patients with B-cell #lymphoma. [Mouse] [Precinical study] [Report] NOTES: - Fecal samples from patients who responded to CAR T-cell therapy had a higher prevalence of #Akkermansia_muciniphila at baseline. - Akkermansia spp. supplementation resulted in greater reductions in tumor volume at 10 days , 34 days, and 46 days after CAR T-cell administration. - Overall survival was significantly improved in mice that Received Akkermansia spp. - Mice that received Akkermansia spp. had higher infiltration of CAR-T cells in the tumor at day 24 than mice that received CAR-T cells alone (30% and 3.6%, respectively). - CAR T-cell infiltration in the bone marrow at day 7 was also higher with the combination than with CAR-T cells alone (1.3% and 0.8%, respectively). - The patients who had high prevalence of Akkermansia spp. also experienced higher #tumor and bone marrow infiltration of CAR-T cells “with a higher #cytotoxic profile and a higher release of #interferon_gamma. https://lnkd.in/eVdiEfKZ

📃Scientific paper: Distinguishing benign and malignant thyroid nodules using plasma trimethylamine N-oxide, carnitine, choline and betaine Abstract: Purpose Trimethylamine N-oxide (TMAO), a gut microbiome–derived metabolite, and its precursors (carnitine, choline, betaine) have not been fully examined in relation to thyroid cancer (TC) risk. The aim of this study was to assess the value of TMAO and its precursors in diagnosis of benign and malignant thyroid nodules. Methods In this study, high-performance liquid chromatography-tandem mass spectrometry was utilized to measure the levels of plasma TMAO and its precursors (choline, carnitine, and betaine) in 215 TC patients, 63 benign thyroid nodules (BTN) patients and 148 healthy controls (HC). The distribution of levels of TMAO and its precursors among the three groups were compared by the Kruskal–Wallis test. Receiver operating characteristic curve (ROC) analysis was performed to evaluate the sensitivity, specificity, and the predictive accuracy of single and combined biomarkers. Results In comparison to HC, TC showed higher levels of TMAO and lower levels of its precursors (carnitine, choline, and betaine) (all P  < 0.001). Plasma choline ( P  < 0.01) and betaine ( P  < 0.05) were declined in BTN than HC. The levels of carnitine ( P  < 0.001) and choline ( P  < 0.05) were significantly higher in BTN than that in TC group. Plasma TMAO showed lower levels in TC with lymph node metastasis (101.5 (73.1–144.5) ng/ml) than those without lymph node metastasis (131 (84.8–201) ng/ml, P  < 0.05). Combinations of these four metabolites achieved good performance in the di... Continued on ES/IODE ➡️ https://etcse.fr/iOF ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.